Bosnalijek
 | |
| Company type | Public (SASE: BSNLR) |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1951 |
| Headquarters | Sarajevo, Bosnia and Herzegovina |
Key people | Edin Arslanagić (Chief Executive Officer) |
| Products | Solid oral form medicines, ampule medicines, galenic products, non-pharmaceutical chemical products |
| Revenue |  88,056 million BAM (2007)[1] |
| 7,796 million BAM (2007)[1] | |
Number of employees | ~620 (2009) |
| Website | http://www.bosnalijek.ba/ |
Bosnalijek is the largest pharmaceutical company in Bosnia and Herzegovina. The organisation was established in 1951 and employs ~620 workers, out of which more than 50% have university level or higher qualifications. Its product portfolio consists of ~180 products. The company continues investment into R&D. Bosnalijek has established collaboration with several world-leading companies from the industry.[2]
Bosnalijek is present in 22 countries worldwide: all neighbouring southeastern European countries, most eastern European countries, Libya and many French-speaking African countries, several countries from the Arabian peninsula and Caucasus, etc.[3]
In 2005, International Finance Corporation provided Bosnalijek with a €7.5 million loan for the construction of an €18.5 million production and distribution center.[4]
References
- ^ a b Bosnalijek - 2007 financial report
- ^ Short overview of Bosnalijek
- ^ Bosnalijek worldwide
- ^ Summary of Project Information, Project Number 24017[permanent dead link], International Finance Corporation, World Bank Group. Accessed 2008-01-14.
External links
 | This European corporation or company article is a stub. You can help Wikipedia by expanding it. |